Can larotrectinib (Vitaika) be used safely in pediatric patients and its dosage reference

Larotrectinib is a selective TRK inhibitor mainly used to treat solid tumors carrying NTRK gene fusions. Since some childhood tumors (such as infantile fibrosarcoma, certain thyroid cancers and brain tumors, etc.) are often associated with NTRK gene fusion, children are important beneficiaries of larotrectinib. Clinical study data show that larotrectinib is well tolerated in pediatric patients, and most adverse reactions are mild to moderate, such as mild increases in liver function indicators, fatigue or nausea. A few patients may experience dose-related side effects, but the overall safety is high.

Approved by the USFDA and the European Medicines Agency (EMA), larotrectinib is suitable for patients regardless of age, tumor location and histological type, as long as they have NTRK gene fusion and lack effective treatment options. Therefore, the pediatric population is clearly included in the scope of indications. In some clinical trials, the objective response rate of larotrectinib in children with solid tumors has reached more than 70%, and some cases even achieved long-term complete response, showing good clinical application value.

Recommended doses for pediatric patients are generally calculated based on body surface area (BSA). The generally recommended dose is 100 mg/m², taken orally twice daily, but a single dose should not exceed 100 mg. For infants and young children who have difficulty swallowing capsules, oral solution formulations are also available for easier administration. The actual dosage needs to be adjusted individually by the attending physician based on the child's body surface area, liver and kidney function, and adverse reactions. If necessary, the dosage can be reduced or the medication can be suspended.

When using larotrectinib in pediatric patients, regular monitoring is required, including evaluation of liver function, blood routine, and neurological symptoms. Once obvious adverse reactions occur, the dose should be adjusted promptly or treatment should be suspended. At the same time, parents should avoid adjusting or changing medications on their own and must use medications in a standardized manner under the guidance of a professional doctor. Overall, larotrectinib provides a new treatment option for NTRK fusion-positive pediatric patients, but long-term follow-up and close monitoring are still required during treatment to ensure efficacy and safety.

Reference link:https://www.drugs.com